Skip to main content
Diabetes Therapy logoLink to Diabetes Therapy
. 2015 Feb 27;6(1):99. doi: 10.1007/s13300-015-0102-6

Erratum to: Starting Insulin in Type 2 Diabetes: Real-World Outcomes After the First 12 Months of Insulin Therapy in a New Zealand Cohort

Shekhar Sehgal 1,, Manish Khanolkar 2
PMCID: PMC4374071  PMID: 25720340

Erratum to: Diabetes Ther DOI 10.1007/s13300-015-0100-8

In the Introduction, the sentence “The IDF guidelines recommend starting with a long-acting basal insulin analog, with pre-mixed insulin for those with higher HbA1C” should read:

“The IDF guidelines recommend starting with a long-acting basal insulin, and suggest starting with pre-mixed insulins for those with a higher starting HbA1C.”

The Conflict of interest section should read:

Manish Khanolkar has consulted in an advisory capacity and recieved speaker’s fees for Eli Lilly, Sanofi Aventis and Novo Nordisk. Shekhar Sehgal declares that he has no conflict of interest.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Footnotes

The online version of the original article can be found under doi:10.1007/s13300-015-0100-8.

Contributor Information

Shekhar Sehgal, Email: shrike59@gmail.com.

Manish Khanolkar, Email: ManishK@adhb.govt.nz.


Articles from Diabetes Therapy are provided here courtesy of Springer

RESOURCES